Si-Bone
Develops an implant to tackle lower back pains.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $77.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 9 % | 23 % | 18 % | 31 % | 20 % | 18 % | 16 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (51 %) | (57 %) | (55 %) | (25 %) | (14 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (60 %) | (63 %) | (58 %) | (31 %) | (18 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 13 % | 14 % | 13 % | 11 % | 10 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
SI-BONE was founded with a mission to address a significant unmet need in the orthopedic field. The company was established by Dr. Mark Reiley, a renowned orthopedic surgeon, who identified the potential to improve treatments for sacroiliac joint dysfunction, a common source of lower back pain. Alongside co-founders Jeff Dunn and Laura Francis, Dr. Reiley set out to revolutionize the approach to this condition.
In its early days, SI-BONE focused on developing a minimally invasive surgical implant system known as iFuse. This system was designed to provide a less invasive option for patients suffering from sacroiliac joint dysfunction, offering a quicker recovery time compared to traditional surgical methods.
The company's journey was marked by significant milestones, including securing FDA clearance for its iFuse Implant System. This regulatory approval was a critical step that allowed SI-BONE to expand its reach and impact in the medical community.
In 2018, SI-BONE achieved a major milestone by going public. The company's Initial Public Offering (IPO) on the NASDAQ provided the capital needed to further its research and development efforts and expand its market presence. This move not only validated SI-BONE's innovative approach but also positioned it for future growth in the competitive medical device industry.
Today, SI-BONE continues to lead in the field of sacroiliac joint treatment, driven by a commitment to improving patient outcomes through innovation and education. The company's journey from a visionary idea to a publicly traded entity underscores its role as a pioneer in orthopedic solutions.